Drug Approval | February 05, 2026
Strides Pharma Inc receives USFDA closure report for Chestnut Ridge formulations facility
Inspection included drug device combinations covering our recent filing in nasal sprays domain
Inspection included drug device combinations covering our recent filing in nasal sprays domain
Plant 1 continues to serve as a core manufacturing hub for oral solid dosage forms
The acquisition marks a major step in PAI’s strategy to expand domestic pharmaceutical manufacturing
The new powder formulation gives children and adults living with Rett syndrome greater flexibility and choice in dose volume and taste
Implementing PFAS testing in the early development stages allows medical device manufacturers to prepare for potential regulatory updates
It will produce a comprehensive range of dosage forms including tablets, hard gelatin capsules, liquids, injectables, topicals, and beta-lactam products
The Ma’anshan site approval covers pastilles, oral liquids, and powders
It offers clear environmental benefits, lower emissions, reduced hazardous material use, and alignment with circular economy goals
This project shall be implemented through incorporation of a new joint venture company in Zambia
The transaction aligns with Aurobindo’s strategic objective to expand its U.S. manufacturing footprint by enhancing its existing domestic capabilities
Subscribe To Our Newsletter & Stay Updated
